

# **Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas**

**James M. Musser, MD, PhD<sup>1</sup>; Paul A. Christensen, MD<sup>1</sup>; Randall J. Olsen, MD, PhD<sup>1</sup>; S. Wesley Long, MD, PhD<sup>1</sup>; Sishir Subedi, MS<sup>1</sup>; James J. Davis, PhD<sup>2</sup>; Parsa Hodjat, MD<sup>1</sup>; Debbie R. Walley MD<sup>1</sup>; Jacob C. Kinskey, MD<sup>1</sup>; Jimmy Gollihar PhD<sup>3</sup>**

<sup>1</sup>Center for Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas

<sup>2</sup>Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, Illinois

<sup>3</sup>CCDC Army Research Laboratory-South, Austin, Texas

**Corresponding Author:** James M. Musser, MD, PhD, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Houston Methodist Research Institute, Houston, TX 77030 ([jmmusser@houstonmethodist.org](mailto:jmmusser@houstonmethodist.org)).

## Abstract

Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic, and disease in individual patients. Delta variants (B.1.617.2, AY.2, and AY.3) are now the focus of international concern because they are causing widespread COVID-19 disease globally. Vaccine breakthrough cases caused by SARS-CoV-2 variants also are of considerable public health and medical concern worldwide. As part of a comprehensive project, we sequenced the genomes of 4,920 SARS-CoV-2 from patient samples acquired March 15, 2021 through July 24, 2021 in the Houston Methodist hospital system and studied vaccine breakthrough cases. During the study period Delta variants increased to cause 94% of all COVID-19 cases and spread throughout the metropolitan Houston area. In addition, Delta variants caused a significantly higher rate of vaccine breakthrough cases (17.4% compared to 5.8% for all other variants). Importantly, only 8.4% of all COVID-19 cases occurred in fully vaccinated individuals, and relatively few of these patients required hospitalization. Individuals with vaccine breakthrough cases caused by Delta variants ( $n = 194$ ) had a low median PCR cycle threshold (Ct) value (a proxy for high virus load), and this value was not significantly different than the median Ct value observed in unvaccinated patients with COVID-19 caused by Delta variants. These data are consistent with the potential ability of fully vaccinated individuals to transmit SARS-CoV-2 to others. Our genomic and epidemiologic data emphasize that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.

## [Text]

Delta variants (B.1.617.2, AY.2, and AY.3) have become the focus of intense international concern because they are causing widespread COVID-19 disease in Southeast Asia, Europe, the United States, and elsewhere. For example, Delta has rapidly replaced the Alpha variant in the United Kingdom, previously the cause of virtually all COVID-19 cases in that country. Vaccine breakthrough cases caused by SARS-CoV-2 variants also have become of considerable public health and biomedical interest worldwide<sup>1-4</sup>. To study Delta and vaccine breakthrough cases in metropolitan Houston, we sequenced the genomes of 4,920 SARS-CoV-2 from patient samples acquired March 15, 2021 through July 24, 2021 using an Illumina NovaSeq 6000 instrument<sup>5</sup>. This period encompasses the time from initial identification of a Delta-related variant in our large Houston Methodist healthcare system until Delta variants became the supermajority (93.7%) of all new cases. The sample is 85% of the 5,756 cases of COVID-19 diagnosed in our health system during this period. Delta variants were identified based on genome sequence data as designated by Pangolin (<https://cov-lineages.org/pangolin.html>). During the study period 1,118 patients were diagnosed with Delta variants, and 414 of the 4,920 patients (8.4%) met the CDC definition of vaccine breakthrough cases (Table 1A). Breakthrough cases received either the Pfizer-BioNTech BNT162b2 ( $n = 353$ , 85%), Moderna mRNA-1273 ( $n = 47$ , 11%), or J&J/Janssen JNJ-78436735 ( $n = 8$ , 2%) vaccines, generally reflecting the supermajority of BNT162b2 vaccinations in our health system; vaccine type was not specified for six individuals. Fourteen patients with Delta Plus (Delta plus the K417N spike polymorphism) were identified, all diagnosed in July. Consistent with extensive

infections caused by Delta variants in Southeast Asia and elsewhere, several patients had very recent travel histories to countries with a high prevalence of these variants, suggesting acquisition abroad and importation into Houston. Patients with Delta variants were identified in 193 zip codes throughout the metropolitan area. Greater than 70 Delta subvariants were identified, likely reflecting the large population sizes and genetic diversity of Delta globally and in Houston and multiple introductions into the Houston metropolitan area. Patients infected with the same subvariant usually lived in different zip codes and had no apparent epidemiological link, consistent with the ability of Delta to spread very rapidly.

There is a considerable lack of detailed information about patients in the United States with COVID-19 caused by Delta variants. Compared to all other patients, Delta patients were not significantly different in median age or gender but did have a slight but significantly longer hospital length of stay (Table 1A). However, significantly fewer Delta patients required hospitalization and fewer required supplemental oxygen. Delta cases were more likely to be Caucasian or Asian (supporting the likelihood of multiple recent entry points) and less likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values (a proxy for higher virus load, a finding consistent with the reported increased transmissibility of Delta variants) on initial diagnosis, and cause a significantly higher rate of vaccine breakthrough cases (17.4% compared to 5.8% for all other variants) (Table 1A).

We next examined metadata for the 414 vaccine breakthrough cases (Table 1B). Vaccinated patients had a significantly higher Ct, likely indicating lower virus load on initial diagnosis. A significantly lower percentage of patients with Delta breakthrough

cases was admitted to hospital (Table 1B). Individuals with vaccine breakthrough cases caused by Delta variants ( $n = 194$ ) had a low median PCR cycle threshold (Ct) value (a proxy for high virus load), and this value was not significantly different than the median Ct value observed in unvaccinated patients with COVID-19 caused by Delta variants. On the presumption that there is a correlation between Ct value and live virus burden, these data are consistent with the potential ability of fully vaccinated individuals to transmit SARS-CoV-2 to others. Similarly, a high load of Delta in these two groups of patients may increase the possibility of generating additional variants with increased fitness, for example escape mutants that further circumvent host immunity.

Our genome sequence data coupled with patient metadata document a very rapid increase and spread of Delta variant cases in metropolitan Houston and a considerable corresponding decrease of COVID-19 cases caused by Alpha, findings similar to epidemiologic trends observed in the UK. Delta was significantly more likely to cause a vaccine breakthrough case (Table 1A). However, importantly, only 8.4% of all COVID-19 cases occurred in fully immunized individuals, and relatively few of these patients required hospitalization. In the aggregate, our data add critical new information to the finding that these three vaccines are highly efficacious in decreasing severe COVID-19 disease, hospitalizations, and deaths.

**Author Contributions:** Drs. Musser, Christensen, Olsen, and Long had full access to all study data and take responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* Musser, Christensen, Olsen, Long

*Data acquisition, analysis, or interpretation of data:* All authors

*Drafting of the manuscript:* All authors

*Statistical analysis:* Christensen

*Obtained funding:* Musser and Davis

*Supervision:* Musser

*Authorship:* Musser, Christensen, Olsen, and Long contributed equally and are co-first authors

**Conflict of Interest Disclosures:** The authors report no conflict of interest.

**Institutional Review Board statement:** This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).

**Funding/Support:** The research was supported by the Houston Methodist Academic Institute Infectious Diseases Fund and many generous Houston philanthropists. James Davis was funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076.

**Role of Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The findings and conclusions in this article are those of the authors and do not necessarily reflect the views of the U.S. Army.

**Additional Contributions:** We are indebted to Drs. Marc Boom and Dirk Sostman for their ongoing support. We thank Matthew Ojeda Saavedra, Prasanti Yerramilli, Layne Pruitt, Kristina Reppond, Madison N. Shyer, Jessica Cambric, Ryan Gadd, Rashi M. Thakur, Akanksha Batajoo, Regan E. Mangham, Sindy J. Pena, and Trina Trinh for technical support. We acknowledge the assistance of Robert Olson, Maulik Shukla and Marcus Nguyen at the Bacterial and Viral Bioinformatics Resource Center for their assistance with sequence analysis. We thank Drs. Sasha Pejerrey and Kathryn Stockbauer for editorial contributions.

**Additional Information:** Genome data used in this study have been deposited to GISAID.

## References

1. Hacısuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* 2021;384:2212-8.
2. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect* 2021.
3. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:792-3.
4. Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nat Med* 2021.
5. Olsen RJ, Christensen PA, Long SW, et al. Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences. *medRxiv* 2021:2021.05.20.21257552.



**Table 1A. Summary of pertinent patient metadata for the 4,920 unique patients**

	Delta Variant	Other Variants	Total	Statistical Analysis
<b>No. (%) with data</b>	1118 (22.7%)	3802 (77.3%)	4920	
<b>Patient Characteristics</b>				
Median Age (Years)	45.7	47.9	47.4	$P=0.1026$ Mann-Whitney
Female	594 (53.1%)	1979 (52.1%)	2573 (52.3%)	$P=0.5399$ Fisher's exact test
Male	524 (46.9%)	1823 (47.9%)	2347 (47.7%)	
<b>Ethnicity</b>				
Caucasian	486 (43.5%)	1485 (39.1%)	1971 (40.1%)	$P=0.0005$ Chi-square
Hispanic or Latino	273 (24.4%)	1160 (30.5%)	1433 (29.1%)	
Black	261 (23.3%)	886 (23.3%)	1147 (23.3%)	
Asian	51 (4.6%)	110 (2.9%)	161 (3.3%)	
Native American	3 (0.3%)	15 (0.4%)	18 (0.4%)	
Hawaiian/Pacific Islander	3 (0.3%)	5 (0.1%)	8 (0.2%)	
Unavailable	35 (3.1%)	114 (3.0%)	149 (3.0%)	
<b>BMI</b>				
Median BMI	29.3	30.3	30.1	$P<0.0001$ Mann-Whitney
<b>Admission Data</b>				
Admitted	457 (40.9%)	2075 (54.6%)	2532 (51.5%)	$P<0.0001$ Fisher's exact test  Odds Ratio: 0.575 (95% CI 0.503 to 0.659)
Not Admitted	661 (59.1%)	1727 (45.4%)	2388 (48.5%)	
Median LOS (Days)	5.3	5.0	5.0	$P=0.0317$ Mann-Whitney

<b>Max Respiratory Support</b>				
Mechanical Ventilation/ECMO	27 (5.9%)	169 (8.1%)	196 (7.7%)	<i>P</i> <0.0001 Chi-square
Supplemental Oxygen	244 (53.4%)	1424 (68.6%)	1668 (65.9%)	
Room Air	186 (40.7%)	482 (23.3%)	668 (26.4%)	
<b>Mortality</b>				
Alive	1103 (98.7%)	3650 (96.0%)	4753 (96.6%)	<i>P</i> <0.0001 Fisher's exact test  Odds Ratio: 0.327 (95% CI 0.194 to 0.558)
Deceased	15 (1.3%)	152 (4.0%)	167 (3.4%)	
<b>Median PCR Cycle Threshold</b>				
Abbott Alinity	20.67 n = 413	25.74 n = 1375	n = 1788	<i>P</i> <0.0001 Mann-Whitney
Hologic Panther	21.0 n = 105	25.75 n = 456	n = 561	<i>P</i> <0.0001 Mann-Whitney
<b>Vaccine</b>				
No vaccine	913 (81.7%)	3444 (90.6%)	4357 (88.6%)	<i>P</i> <0.0001 Chi-square
>7 days past 1st vaccine	11 (1.0%)	138 (3.6%)	149 (3.0%)	
>14 days past 2nd vaccine	194 (17.4%)	220 (5.8%)	414 (8.4%)	

Data include 4,920 unique patients with high-quality sequence results between March 15, 2021, and July 24, 2021.

BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

**Table 1B. Summary of pertinent patient metadata for the 414 fully vaccinated patients**

	Vaccinated	Not Vaccinated	Total	Statistical Analysis
<b>Median PCR Cycle Threshold</b>				
Abbott Alinity	27.03 n = 190	24.09 n = 1598	n = 1788	P=0.0080 Mann-Whitney
Hologic Panther	27.35 n = 48	24.5 n = 513	n = 561	P=0.0767 Mann-Whitney
<b>Median PCR Cycle Threshold (Delta variant only)</b>				
Abbott Alinity	20.67 n = 87	20.67 n = 326	n = 413	P=0.9231 Mann-Whitney
Hologic Panther	20.60 n = 17	21.1 n = 88	n = 105	P=0.9514 Mann-Whitney
<b>Median PCR Cycle Threshold (Non-Delta only)</b>				
Abbott Alinity	35.77 n = 103	25.31 n = 1272	n = 1375	P<0.0001 Mann-Whitney
Hologic Panther	35.5 n = 31	25.5 n = 425	n = 456	P=0.0017 Mann-Whitney
<b>Admission Data</b>				
Admitted	147 (35.5%)	2385 (52.9%)	2532 (51.5%)	P<0.0001
Not Admitted	267 (64.5%)	2121 (47.1%)	2388 (48.5%)	Fisher's exact test  Odds Ratio: 0.490 (95% CI 0.396 to 0.602)

	<b>Delta Variant</b>	<b>Other Variants</b>	<b>Total</b>	
<b>No. (%) with data</b>	194 (46.9%)	220 (53.1%)	414	
<b>Cancer History</b>				
Yes	22 (11.3%)	27 (12.3%)	49 (11.8%)	P=0.8790
No	172 (88.7%)	193 (87.7%)	365 (88.2%)	Fisher's exact test  Odds Ratio: 0.914 (95% CI 0.508 to 1.677)
<b>Admission Data</b>				
Admitted	56 (28.9%)	91 (41.4%)	147 (35.5%)	P=0.010
Not Admitted	138 (71.1%)	129 (58.6%)	267 (64.5%)	Fisher's exact test  Odds Ratio: 0.575 (95% CI 0.384 to 0.866)